A New Natural Antimycotic Agent is Effective Against Oropharyngeal Candidiasis: The VIPROCAN Study
Josefa Carrión-Navarro1, Alejandra Argüelles2, María Lara Martínez-Gimeno3, Alejandro Tovar Lozada4, Angel Ayuso-Sacido1, 5, Cristobal Belda-Iniesta6, Mercedes Arnás-Rodríguez4, Noemí García-Romero1 , *
Identifiers and Pagination:Year: 2022
E-location ID: e187421062202010
Publisher ID: e187421062202010
Article History:Received Date: 7/10/2021
Revision Received Date: 10/11/2021
Acceptance Date: 2/12/2021
Electronic publication date: 25/04/2022
Collection year: 2022
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The incidence of community and nosocomial candidiasis has dramatically increased in the last two decades. There are multiple treatments for this infection, but the toxicity of some and the induction of resistant strains require the development of new compounds.
With the aim of reducing the Candida population in the oropharyngeal cavity, we have formulated a toothpaste with VG-01 agent, composed of a mixture of carnosic acid (CA) and propolis (PP).
We investigated the ability of VG-01 toothpaste to minimize and stabilize fungal presence in 21 patients diagnosed with clinical oropharyngeal candidiasis.
Our data indicate that VG-01 toothpaste showed an effect not only against the most frequent species of Candida, C. albicans, but also in the other species analyzed. 82% of patients stated that they would continue using it outside the study.
Our data demonstrate that VG-01, composed of CA and PP is a potential antimycotic agent effective against the most common species that cause oropharyngeal candidiasis present in clinical practice.